Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Executive Summary
The Phase III failure of the Alzheimer’s treatment was largely expected, but is nonetheless a disappointment for the disease and for the anti-amyloid field, casting a shadow over other therapies in development, including Lilly’s own pipeline.
You may also be interested in...
Lilly’s New Anti-Amyloid Play Hinges On Tau Bet
TRAILBLAZER-ALZ met the primary, but not most secondary endpoints. Lilly said efficacy of its amyloid-clearing agent depends on tau levels at baseline and reductions in some parts of the brain.
An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.
An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.